GT Biopharma could report Phase 1 trial data later this year, says Roth MKM

GT Biopharma (GTBP) ended 2024 with roughly $4M in cash, enough to fund operations into the second quarter of 2025, Roth MKM tells investors in a research note. The firm, which has a Buy rating and $11 price target on the shares, believes GT will be able to release initial data from its Phase 1 trial evaluating second-generation TriKE GTB-3650 in rel/ref CD33 expressing hematologic malignancies like Acute Myeloid Leukemia and high-risk Myelodysplastic Syndromes, later this year.